Literature DB >> 10687946

Glottic and supraglottic laryngeal carcinoma: differences in epidemiology, clinical characteristics and prognosis.

H Raitiola1, J Pukander, P Laippala.   

Abstract

In order to evaluate differences in epidemiology, clinical characteristics and prognosis, 166 glottic and 127 supraglottic cases of laryngeal squamous cell carcinoma diagnosed between 1962 and 1991 at Tampere University Hospital, Finland, were reviewed. The annual age-adjusted incidence in males decreased from 6.7/100,000 to 2.6/100,000 and the proportion of glottic tumours increased from one-third to two-thirds during the study period. The proportion of early stage lesions was greater among glottic tumours, and patients with a supraglottic tumour presented more often with neck node metastases. Hoarseness was the most common symptom, being more prevalent in patients with a glottic tumour. The symptom pattern of supraglottic carcinoma was altogether more diffuse. The 5-year disease-specific survival was 81% in glottic and 70% in supraglottic disease, but the difference in survival was not statistically significant. In the multivariate Cox regression analysis, higher T-category and presence of neck node metastases had adverse prognostic effect, while location of the tumour did not significantly affect the prognosis. Favourable changes in smoking habits seem to be the main reason for the incidence decrease and obviously also for the decrease in the proportion of supraglottic tumours.

Entities:  

Mesh:

Year:  1999        PMID: 10687946     DOI: 10.1080/00016489950180531

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  15 in total

1.  Differential beta-catenin expression between glottic and supraglottic laryngeal carcinoma.

Authors:  Anastasios K Goulioumis; John Varakis; Panos Goumas; Helen Papadaki
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-04-18       Impact factor: 2.503

2.  Multiple chromosomal underrepresentations detected by interphase cytogenetics - possible prognostic markers in head and neck tumors?

Authors:  B Kleist; A Bankau; G Lorenz; M Poetsch
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 3.  Effects of tumour stage, comorbidity and therapy on survival of laryngeal cancer patients: a systematic review and a meta-analysis.

Authors:  Elisabeth Rudolph; Gerhard Dyckhoff; Heiko Becher; Andreas Dietz; Heribert Ramroth
Journal:  Eur Arch Otorhinolaryngol       Date:  2010-10-19       Impact factor: 2.503

4.  Long-term trends in gender, T-stage, subsite and treatment for laryngeal cancer at a single center.

Authors:  Jesper Brandstorp-Boesen; Ragnhild Sørum Falk; Morten Boysen; Kjell Brøndbo
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-29       Impact factor: 2.503

5.  The epidemiology of laryngeal cancer in a country on the esophageal cancer belt.

Authors:  Babak Saedi; Ebrahim Razmpa; Mohammad Sadeghi; Mohammad Mojtahed; Ali Mojtahed
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2009-09-27

6.  Glottic versus supraglottic tumors: differential molecular profile.

Authors:  Konstantinos Kourelis; Theodoros Papadas; Gerasimos Vandoros; Panos Goumas; Georgia Sotiropoulou-Bonikou
Journal:  Eur Arch Otorhinolaryngol       Date:  2007-10-02       Impact factor: 2.503

7.  MAP17 (PDZKIP1) as a novel prognostic biomarker for laryngeal cancer.

Authors:  María-José de Miguel-Luken; Manuel Chaves-Conde; Verónica de Miguel-Luken; Sandra Muñoz-Galván; José Luis López-Guerra; Juan C Mateos; Jerónimo Pachón; David Chinchón; Vladimir Suarez; Amancio Carnero
Journal:  Oncotarget       Date:  2015-05-20

8.  Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival.

Authors:  María José de Miguel-Luken; Manuel Chaves-Conde; Begoña Quintana; Alicia Menoyo; Isabel Tirado; Verónica de Miguel-Luken; Jerónimo Pachón; David Chinchón; Vladimir Suarez; Amancio Carnero
Journal:  Oncotarget       Date:  2016-05-31

9.  Impact of stage, management and recurrence on survival rates in laryngeal cancer.

Authors:  Jesper Brandstorp-Boesen; Ragnhild Sørum Falk; Morten Boysen; Kjell Brøndbo
Journal:  PLoS One       Date:  2017-07-14       Impact factor: 3.240

10.  Supraglottic laryngeal mass.

Authors:  Laura Andrews; Sean O Henderson
Journal:  West J Emerg Med       Date:  2009-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.